Patent intelligence · US
US 6096727
Method for treating wounds using modified hyaluronic acid crosslinked with biscarbodiimide
Method for treating wounds using modified hyaluronic acid crosslinked with biscarbodiimide
Patent details — US 6096727
- Jurisdiction
- US
- Status
- expired
- Grant date
- Aug 1, 2000
- Expiration
- Jul 27, 2020
- Applicant
- ANIKA THERAPEUTICS, INC.
- Claims
- 8
- CPC classes
- A61K, A61K47/36, A61K47/61, A61K47/6903
Quick answer
US 6096727 (Method for treating wounds using modified hyaluronic acid crosslinked with biscarbodiimide) is held by ANIKA THERAPEUTICS, INC.. Status: expired. Granted Aug 1, 2000. Expires Jul 27, 2020 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ANIKA THERAPEUTICS, INC.
- Grant date
- Expiration
- Claims
- 8
- CPC classes
- A61K, A61K47/36, A61K47/61, A61K47/6903, A61K9/0014, A61K9/0019
More from ANIKA THERAPEUTICS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12415779
Processes of making 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)-benzonitrile and polymorphs thereof
granted -
US 12391642
Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors
granted -
US 12331026
Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors
granted -
US 12264167
Fused tricyclic ring derivatives as SRC homology-2 phosphate inhibitors
granted -
US 12171741
2,3-dihydrobenzo[b]thiophene derivatives as hypoxia inducible factor-2(alpha) inhibitors
granted -
US 12077506
Indane derivatives as hypoxia inducible factor-2(α) inhibitors
granted -
US 11939303
Sulfamate derivatives of 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenol, derivatives of 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenol, their medical use and the method of obtaining 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenyl sulfamate derivatives
granted -
US 11753366
Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors
granted
Frequently asked questions
What is US patent 6096727?
US 6096727 (Method for treating wounds using modified hyaluronic acid crosslinked with biscarbodiimide) is held by ANIKA THERAPEUTICS, INC.. Status: expired. Granted Aug 1, 2000. Expires Jul 27, 2020 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6096727?
ANIKA THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 69 pharmaceutical patents for this assignee.
When does US 6096727 expire?
Our index shows an expiration date of Jul 27, 2020 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.